SMN2 gene

Isis Pharmaceuticals has launched a phase 2 trial to test its experimental antisense drug ISIS-SMNRx in infants with spinal muscular atrophy

posted on May 7, 2013 - 12:15pm
  Update (Jan. 14, 2014): Contact information for Isis Pharmaceuticals has been changed. Update (Nov. 4, 2013): All centers are now recruiting participants.
posted on May 1, 2007 - 10:27pm
QUEST Vol. 14, No. 3
Research progress in spinal muscular atrophy (SMA) has been considerable in recent months.